Data for: A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin followed by Lenalidomide (GROC-Rev)

Name: Data for: A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin followed by Lenalidomide (GROC-Rev)
Creator: Fernando Cabanillas
Published: 2019-10-04T14:52:12.809Z
Keywords: Malignant Hematology

Cabanillas, Fernando; Liboy, Idalia; Pardo, Wandaly; Solivan, Pedro; Acosta, Mirelis; Rivera, Noridza

doi:10.17632/mkdw5wnkgf.1

Data for: A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin followed by Lenalidomide (GROC-Rev)

Published: 4 October 2019| Version 1 | DOI: 10.17632/mkdw5wnkgf.1

Contributors:

Fernando Cabanillas, Idalia Liboy, Wandaly Pardo, Pedro Solivan, Mirelis Acosta, Noridza Rivera

Description

No optimal salvage therapy for relapsed/refractory aggressive histological types of non-Hodgkin lymphoma exists. We explored a combination of single-agent lenalidomide following gemcitabine, rituximab, oxaliplatin combination (“GROC-Rev”) in 33 patients. We observed a response rate of 61% (39% complete response rate) and 3-year overall survival of 47%, superior to previous experience. GROC-Rev is a new salvage regimen with encouraging results.

Data for: A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin followed by Lenalidomide (GROC-Rev)

Description

Files

Categories

Licence